• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Ocular/ Adnexal Tumors  • Dermatology  • Surgery  • Melanoma  • Surgical Physiology, Other  • Diagnosis  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

An Immunohistochemical Study of 123 Cases

Emiko Furusato, MD; Ahmed A. Hidayat, MD; Yan-Gao Man, MD, PhD; Aaron Auerbach, MD, MPH; Bungo Furusato, MD; Elisabeth J. Rushing, MD

Arch Ophthalmol. 2009;127(8):964-969.

Objective  Recent studies indicate that WT1 and Bcl2 protein are detected in melanocytic lesions of the skin. We examined, for the first time, WT1 and Bcl2 expression in a variety of conjunctival melanocytic lesions to evaluate their diagnostic utility compared with other melanocytic markers.

Methods  Protein expression and localization of WT1 and Bcl2 were studied by means of immunolabeling and semiquantification in 123 conjunctival melanocytic lesions (71 benign nevi, 21 atypical nevi, 11 primary acquired melanosis, and 20 malignant melanomas). Ancillary immunohistochemical studies were performed with Bcl2, S100, HMB45, and Melan A antibodies.

Results  WT1 showed a graded increase in expression in lesions with increasing atypia. Higher mean numbers of WT1-positive cells correlated with increasing atypia in melanocytes. In all cases, Bcl2 expression was positive and more robust than was S100, HMB45, or Melan A expression. WT1 and HMB45 frequently showed diffuse and strong staining in atypical nevi, primary acquired melanosis with atypia, and malignant melanomas compared with benign lesions.

Conclusions  Bcl2 is a highly sensitive immunohistochemical marker for melanocytic tumors of the conjunctiva; HMB45 and WT1 staining distinguishes benign from malignant lesions.

Clinical Relevance  Our results show that HMB45 and WT1 immunolabeling is helpful in the evaluation of conjunctival melanocytic lesions. Accordingly, we recommend the development of an immunohistochemical panel to classify these lesions.

Author Affiliations: Departments of Neuropathology and Ophthalmic Pathology (Drs E. Furusato, Hidayat, and Rushing), Gynecologic Pathology (Dr Man), Hematopathology (Dr Auerbach), and Genitourinary Pathology (Dr B. Furusato), Armed Forces Institute of Pathology, Washington, District of Columbia.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma
Westekemper et al.
Br J Ophthalmol 2011;95:853-858.
ABSTRACT | FULL TEXT  

Immunohistochemical Studies of Conjunctival Nevi and Melanomas
Jakobiec et al.
Arch Ophthalmol 2010;128:174-183.
ABSTRACT | FULL TEXT